background
preexist
immun
vaccinia
tian
tan
viru
vtt
result
larg
vaccin
campaign
smallpox
prior
earli
china
major
issu
applic
vttvector
base
vaccin
essenti
establish
sensit
highthroughput
neutral
assay
understand
epidemiolog
vacciniaspecif
immun
current
popul
china
new
antivaccinia
viru
vacv
neutral
assay
use
attenu
replicationcompet
vtt
carri
firefli
luciferas
gene
photinu
pyrali
rtvfluc
establish
standard
critic
paramet
includ
choic
cell
line
viral
infect
dose
infect
time
current
studi
evalu
mainten
virusspecif
immun
smallpox
vaccin
conduct
nonrandom
crosssect
analysi
antivir
antibodymedi
immun
respons
volunt
examin
year
vaccin
rtvfluc
neutral
assay
abl
detect
neutral
antibodi
nab
vaccinia
viru
without
abil
differenti
strain
vaccinia
viru
show
neutral
titer
measur
assay
similar
obtain
tradit
plaqu
reduct
neutral
test
prnt
use
assay
found
low
preval
nab
vtt
individu
born
beij
anhui
provinc
china
present
antivtt
nab
titer
low
nab
detect
sampl
individu
born
signific
differ
observ
titer
preval
gender
age
rang
geograph
origin
conclus
simplifi
sensit
standard
reproduc
highthroughput
assay
develop
quantit
nab
differ
vaccinia
strain
current
studi
provid
use
insight
futur
develop
vttbase
vaccin
beij
anhui
provinc
china
vaccinia
tian
tan
viru
vtt
histor
use
vaccin
million
chines
peopl
worldwid
smallpox
prevent
campaign
program
led
erad
variola
china
prior
recent
year
vtt
use
viru
vector
develop
potenti
vaccin
human
immunodefici
viru
hiv
hepat
b
viru
hbv
human
papillomaviru
hpv
influenza
viru
subtyp
aichi
viru
aiv
sever
acut
respiratori
syndrom
coronaviru
sarscov
rabi
viru
confer
protect
immun
anim
although
approach
success
anim
model
signific
problem
remain
use
vtt
vector
human
current
view
vaccinia
viru
vacv
suggest
immun
high
exist
current
popul
born
earli
may
influenc
titer
durat
antibodi
respons
induc
second
distinct
vaccinia
recombin
vaccin
preexist
immun
viral
vector
major
issu
applic
vtt
vectorbas
vaccin
human
therefor
highthroughput
neutral
assay
urgent
need
assess
level
immun
vacv
current
popul
neutral
assay
would
also
use
monitor
effici
vaccin
experiment
clinic
set
allow
standard
worldwid
convent
method
use
determin
antivaccinia
neutral
antibodi
titer
plaqu
reduct
neutral
test
prnt
prnt
consid
gold
standard
assay
specif
direct
reproduc
howev
prnt
timeconsum
laborintens
applic
largescal
screen
need
popul
survey
recent
year
sever
assay
develop
highthroughput
semiautom
reli
plaqu
format
manual
count
assay
detect
aggreg
cell
infect
indic
enzym
immunoassay
express
recombin
report
gene
bgalactosidas
bgal
green
fluoresc
protein
gfp
perceiv
difficulti
assay
may
includ
use
cell
suspens
cultur
gfp
assay
may
labori
maintain
lower
dynam
rang
observ
enzymat
bgz
assay
describ
develop
novel
neutral
assay
format
use
replicationcompet
vtt
possess
firefli
luciferas
protein
report
gene
rtvfluc
upon
infect
neutral
antibodi
nab
activ
evalu
function
reduct
fluc
activ
presenc
specif
antivaccinia
antibodi
serum
use
fluc
neutral
assay
sever
advantag
report
chloramphenicol
acetyltransferas
cat
bgal
gfp
includ
high
sensit
broad
dynam
rang
simplic
sensit
chemiluminesc
detect
report
greater
fluorescencebas
assay
greater
colorimetr
method
sinc
peopl
vaccin
decad
ago
vaccinia
still
maintain
immun
vtt
futur
vaccin
use
vtt
vectorbas
vaccin
might
affect
thu
import
clarifi
whether
individu
vaccin
decad
ago
maintain
immun
vtt
proport
popul
possess
immun
effect
immun
current
studi
use
novel
rtvfluc
neutral
assay
studi
preval
vttspecif
antibodi
among
repres
current
chines
popul
approxim
round
purif
insert
fluc
vtt
genom
confirm
polymeras
chain
reaction
pcr
express
detect
use
chemiluminesc
assay
amplifi
fluc
product
identifi
exactli
match
publish
sequenc
genbank
access
ml
rtvfluc
viru
stock
lot
number
titer
plaqueform
unit
pfu
ml
aliquot
store
liquid
nitrogen
china
center
type
cultur
collect
wuhan
china
sever
cell
line
compar
use
fluc
assay
differ
dose
rtvfluc
viru
figur
b
luciferas
express
detect
incub
luciferin
substrat
two
cell
line
vero
produc
low
background
similar
control
cef
cell
shown
found
cell
result
cytopath
effect
infect
h
high
dose
group
cell
plate
therefor
cell
line
suitabl
assay
due
high
suscept
rtvfluc
infect
thu
vero
cell
line
chosen
experi
suscept
less
cell
suitabl
lowtit
nab
detect
sinc
vero
cell
slow
growth
rate
cellswel
plate
need
produc
monolay
allow
detect
viral
prolifer
follow
incub
shorter
incub
period
examin
h
incub
period
suffici
distinguish
luciferas
express
infect
cell
background
level
normal
cell
higher
background
moreov
comparison
addit
cellswel
cellswel
plate
favor
higher
cell
densiti
due
better
reproduc
cv
vs
pfuwel
figur
found
wash
phosphatebuff
salin
pb
addit
luciferin
substrat
significantli
decreas
luciferas
antigen
express
compar
wash
figur
f
vero
cell
infect
differ
dose
rtvfluc
determin
optim
concentr
use
neutral
assay
figur
depict
direct
correl
rtvfluc
concentr
luciferas
transgen
express
dynam
rang
viral
infect
dose
cell
increas
express
linearli
correl
increas
viral
infect
dose
next
neutral
activ
vacciniavaccin
rabbit
serum
sampl
determin
compar
differ
rtvfluc
concentr
evalu
optim
multipl
infect
moi
viru
use
assay
figur
poor
viru
neutral
observ
pfuwel
cell
ratio
rabbit
serum
similar
dynam
curv
neutral
infect
obtain
cell
pfu
cell
viru
neutral
decreas
serum
nab
concentr
decreas
lower
pfuwel
ratio
use
correl
decreas
presenc
sampl
high
nab
titer
vtt
assay
refer
rabbit
antiserum
neutral
rtvfluc
pfuwel
ratio
nt
respect
test
serum
sampl
assay
three
time
two
concentr
rtvfluc
confirm
consist
assay
infecti
dose
pfu
moi
middl
linear
rang
chosen
optim
viral
infect
dose
perform
assay
due
lower
coeffici
variat
dose
determin
larg
enough
produc
high
signal
thu
permit
evalu
reduct
transgen
express
follow
neutral
also
low
enough
render
assay
sensit
final
format
rtvfluc
neutral
assay
test
human
sera
describ
tabl
rtvfluc
neutral
assay
abl
detect
nab
rabbit
mous
human
sera
balbc
mice
vaccin
twice
recombin
rtvhivgp
vaccin
contain
env
gene
bc
recombin
three
week
second
administr
sera
collect
analyz
use
rtvfluc
neutral
assay
figur
neutral
activ
detect
sera
two
vaccin
mice
neutral
titer
nt
two
mous
sera
show
signific
neutral
activ
signific
neutral
activ
observ
rabbit
serum
howev
rabbit
serum
collect
two
week
second
vtt
inocul
abl
neutral
rtvfluc
nt
figur
final
sera
obtain
two
human
immun
experiment
hiv
vaccinia
vaccin
recombin
modifi
vaccinia
ankara
rmvahivgp
guangxi
center
diseas
control
cdc
use
detect
neutral
activ
heterolog
rtvfluc
viru
nt
detect
neutral
activ
shown
two
human
sera
figur
addit
rmvahivgp
immun
individu
sera
analyz
neutral
antibodi
shown
figur
peak
level
specif
antimva
nab
detect
earli
two
week
immun
declin
rapidli
undetect
level
vaccine
three
month
taken
togeth
data
show
homolog
heterolog
antivacv
nab
variou
speci
could
detect
use
develop
assay
part
character
new
vaccinia
neutral
assay
import
compar
data
obtain
gener
prnt
serum
titer
obtain
transgen
express
inhibit
replic
inhibit
plaqu
score
compar
maximum
viru
infect
observ
control
well
without
serum
vttantibodi
posit
refer
serum
fb
alon
includ
posit
neg
control
respect
comparison
titer
reveal
nab
titer
human
immun
mous
sera
fluc
assay
higher
prnt
assay
p
figur
moreov
two
serum
sampl
tabl
descript
final
format
luciferas
neutral
assay
human
sera
step
descript
sampl
collect
collect
blood
sampl
venipunctur
inactiv
separ
sera
min
dilut
sera
prepar
seven
dilut
step
flatbottom
plate
final
volum
ul
prepar
ml
medium
nonneutr
viru
control
control
serum
establish
nt
titer
includ
assay
plate
standard
dispens
ml
contain
pfu
vtt
well
incub
co
h
neg
nab
titer
prnt
determin
posit
fluc
assay
nt
analysi
data
use
ttest
figur
indic
experiment
condit
develop
high
correl
exist
two
method
r
thu
establish
newli
develop
luciferas
reportergen
assay
rapid
h
sensit
tradit
prnt
one
import
applic
develop
assay
use
investig
seropreval
preexist
vtt
nab
gener
popul
nab
titer
determin
fluc
assay
three
differ
agerel
cohort
cover
period
cessat
routin
smallpox
vaccin
china
shown
tabl
sera
individu
born
determin
neg
antivtt
nab
titer
overal
percentag
peopl
posit
antivtt
nab
titer
individu
born
percentag
posit
vtt
nab
nt
individu
high
titer
antivtt
antibodi
nt
increas
age
age
group
respect
evid
vttspecif
nab
signific
differ
two
cohort
seroposit
rate
determin
taken
togeth
data
show
develop
assay
sensit
enough
detect
even
low
level
viral
inhibit
nt
neutral
titer
detect
seroposit
sampl
rang
tabl
interestingli
found
even
year
postvaccin
one
individu
maintain
high
level
vacciniaspecif
nab
titer
similar
obtain
antivtt
rabbit
sera
atr
nt
vs
statist
signific
associ
observ
gender
presenc
antibodi
vtt
analyz
sampl
collect
variou
locat
includ
beij
anhui
provinc
found
signific
differ
seroposit
rate
nab
studi
establish
novel
vacvneutr
assay
replac
prnt
base
inhibit
infect
vero
cell
recombin
vtt
carri
firefli
luciferas
gene
result
inhibit
transgen
express
quantit
analysi
use
assay
support
data
show
number
rtvfluc
particl
bound
cell
directli
proport
transgen
express
use
fluc
report
offer
sever
advantag
compar
standard
prnt
follow
higher
resolut
avail
due
precis
measur
firefli
luciferas
transgen
express
amplif
effect
chemiluminesc
ii
greater
reliabl
sinc
data
gather
step
rtvfluc
assay
autom
iii
shorter
overal
assay
time
due
reduct
incub
time
h
vs
iv
higher
throughput
via
format
versu
prnt
v
fivefold
reduct
volum
valuabl
sera
need
analysi
recombin
vacv
express
report
gene
gfp
bgal
may
also
use
establish
highthroughput
sensit
neutral
assay
spranger
et
al
compar
luciferas
activ
autom
quantit
gfp
bgal
protein
express
determin
nab
found
luciferas
activ
detect
sensit
transgen
system
requir
fewer
target
cell
made
suitabl
use
plate
highthroughput
hatakeyama
et
al
note
moder
posit
correl
antibodi
detect
prnt
assay
elisa
among
repres
japanes
popul
due
number
epitop
viral
protein
neutral
epitop
vaccinia
viru
current
studi
examin
import
standard
critic
paramet
includ
choic
cell
line
viral
infect
dose
incub
time
wash
step
could
affect
sensit
reproduc
specif
correl
prnt
assay
adequ
control
paramet
reduc
variabl
titer
valu
allow
reliabl
comparison
data
differ
studi
cell
chosen
base
abil
allow
rtvfluc
replic
produc
cytopath
effect
cpe
follow
h
incub
two
cell
line
vero
primari
chicken
embryo
fibroblast
cef
test
compat
rtvfluc
assay
three
vero
cell
allow
viral
replic
h
without
visibl
cpe
result
obtain
vero
cell
reproduc
determin
optim
viral
concentr
import
infecti
dose
must
low
order
increas
assay
sensit
howev
infect
dose
also
high
enough
produc
signal
allow
measur
reduct
due
neutral
assay
dynam
rang
found
cell
determin
pfu
moi
middl
linear
rang
appropri
reproduc
sensit
linear
correl
obtain
vaccinia
vector
concentr
transgen
fluc
express
support
hypothesi
one
virionon
transduct
event
found
sera
three
differ
speci
differ
level
nonspecif
inhibit
effect
dilut
assay
sampl
consid
posit
inhibit
percentag
reach
fact
sampl
start
dilut
determin
neg
although
inhibit
percentag
rang
thu
inhibit
percentag
affect
result
detect
found
nonspecif
inhibit
effect
decreas
serum
dilut
increas
fold
determin
nonspecif
neutral
effect
could
ignor
serum
dilut
fold
order
test
rtvfluc
assay
sera
healthi
human
individu
born
rtvhivgp
immun
mous
sera
two
week
second
immun
test
comparison
neutral
titer
obtain
rtvfluc
prnt
indic
high
correl
r
moreov
statist
comparison
indic
limit
detect
rtvfluc
assay
lower
prnt
assay
believ
slightli
enhanc
sensit
observ
due
differ
protocol
follow
assay
viru
incub
antibodi
h
howev
rtvfluc
assay
virusantibodi
suspens
dilut
twofold
cell
ad
remov
incub
contrast
antibodi
remov
h
preincub
prnt
liquid
medium
replac
semisolid
overlay
order
obtain
discret
plaqu
neutral
vacv
could
occur
even
viru
attach
cell
henc
new
method
describ
sensit
enough
detect
hightit
lowtit
nab
mous
rabbit
human
serum
sampl
provid
simpl
valid
transfer
laboratori
present
studi
investig
util
rtvfluc
neutral
assay
two
differ
studi
first
studi
assay
use
perform
epidemiolog
studi
ensur
vtt
optim
vaccin
vector
applic
chines
popul
concern
util
recombin
vacv
vectorbas
vaccin
could
limit
high
preval
preexist
vacv
nab
human
popul
liveviru
vectorbas
vaccin
strategi
like
increasingli
use
vacvderiv
vector
futur
clinic
trial
inde
vtt
success
use
viru
vector
develop
hiv
hbv
hpv
aiv
sarscov
rabi
viru
vaccin
confer
protect
immun
anim
howev
signific
problem
remain
use
vtt
vector
human
preexist
immun
viral
vector
preexist
immun
vaccine
viral
vector
like
limit
amount
viru
reach
infect
target
tissu
thu
decreas
express
viru
encod
foreign
antigen
consequ
immun
respons
gener
target
antigen
known
orthopoxviru
serolog
test
elisa
prnt
viru
speci
specif
due
high
level
crossantigen
observ
among
speci
opxv
genu
studi
specif
rtvfluc
assay
analyz
orthopoxviru
howev
determin
antibodi
detect
develop
assay
like
induc
smallpox
erad
campaign
vtt
sinc
strain
use
vaccin
smallpox
china
knowledg
first
studi
preval
potenc
vttspecif
nab
human
sampl
differ
geograph
origin
china
serolog
survey
perform
use
divers
popul
beij
other
anhui
maletofemal
ratio
compris
wide
rang
age
year
age
low
preval
nab
vtt
seen
chines
peopl
born
mostli
low
titer
result
corrobor
immunolog
studi
vacv
specif
antibodi
popul
screen
indic
antivacv
nab
low
stabl
vaccine
year
postvaccin
japan
shuji
hatakeyama
et
al
report
approxim
peopl
born
born
also
found
maintain
nab
vacv
interestingli
also
found
percentag
posit
vtt
nab
titer
china
increas
age
believ
may
due
differ
number
smallpox
vaccin
particip
receiv
preval
preexist
nab
vtt
could
guid
futur
administr
vtt
vectorbas
product
beij
anhui
provinc
sinc
kinet
immun
foreign
antigen
seem
parallel
kinet
vector
second
part
studi
focus
evalu
dynam
antivacv
nab
titer
gener
upon
administr
recombin
mva
vectorbas
vaccin
human
rtvfluc
neutral
assay
describ
abl
detect
specif
humor
respons
elicit
mva
vector
timeand
dosedepend
manner
although
durat
nab
multipl
mva
vector
vaccin
analyz
present
studi
believ
stronger
longlast
immun
could
achiev
primeboost
strategi
current
chines
popul
indic
lai
l
et
al
amanna
et
al
review
smallpox
vaccineinduc
antibodi
respons
necessari
suffici
protect
lethal
monkeypox
infect
present
durat
vacciniaspecif
nab
controversi
studi
demonstr
full
protect
immun
confer
smallpox
vaccin
last
year
even
partial
immun
fade
substanti
year
meanwhil
other
shown
immun
smallpox
may
still
present
mani
year
vaccin
sever
studi
shown
serum
neutral
antibodi
titer
associ
protect
immun
smallpox
diseas
use
level
nab
marker
smallpox
resist
determin
subject
born
china
demonstr
titer
level
believ
low
preval
vtt
nab
due
low
sensit
assay
sensit
rtvfluc
assay
similar
even
slightli
higher
prnt
report
epidemiolog
studi
vacvspecif
nab
gener
popul
china
therefor
unknown
whether
limit
studi
popul
truli
repres
nation
level
antibodi
titer
focu
futur
studi
data
suggest
peopl
born
earli
china
stop
vaccin
smallpox
would
vulner
smallpox
vaccin
older
popul
would
also
vulner
due
low
nab
titer
previou
find
indic
human
memori
b
cell
could
maintain
life
absenc
antigen
reexposur
although
vacv
nab
studi
declin
undetect
level
popul
studi
china
believ
vacvspecif
memori
b
cell
could
activ
rapidli
produc
neutral
antibodi
upon
reimmun
therefor
vacv
recombin
vacv
vectorbas
vaccin
attract
attent
use
vaccin
variola
viru
china
due
rise
bioterror
threat
around
world
event
orthopoxviru
outbreak
speed
highthroughput
natur
rtvfluc
assay
may
prove
extrem
valuabl
summari
simpl
object
reproduc
timeand
laborsav
chemiluminescencebas
neutral
assay
develop
determin
antivacv
nab
titer
human
anim
sera
new
assay
may
good
candid
method
perform
epidemiolog
survey
also
monitor
antivacv
immun
respons
largescal
clinic
trial
moreov
assay
could
also
use
basic
research
sinc
give
direct
measur
neutral
activ
ethic
issu
studi
inspect
approv
ethic
committe
beij
blood
center
particip
inform
purpos
studi
written
consent
also
obtain
particip
involv
studi
vero
atcc
cctcc
cell
use
fluc
neutral
assay
grown
co
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
fb
lglutamin
combin
antibiot
nonessenti
amino
acid
hyclon
south
logan
ut
usa
primari
chicken
embryo
fibroblast
cef
prepar
embryo
grown
dmem
supplement
fb
origin
vtt
strain
deriv
institut
vtt
propag
cef
cell
titer
determin
plaqueform
assay
use
crystal
violet
stain
primari
cef
experi
use
vtt
sera
mice
rabbit
vaccin
vtt
control
normal
mous
rabbit
sera
use
antivtt
rabbit
sera
atr
kindli
provid
dr
huanyu
beij
tiantan
biolog
product
beij
china
sampl
recombin
mvahivgp
virusvaccin
particip
kindli
provid
dr
wei
kong
jilin
univers
changchun
china
serum
sampl
donor
male
femal
rang
age
year
obtain
divers
human
popul
healthi
individu
beij
anhui
provinc
china
known
histori
smallpox
vaccin
neg
control
includ
serum
sampl
obtain
unvaccin
peopl
male
femal
born
year
evalu
specif
nab
vtt
sinc
routin
smallpox
vaccin
discontinu
china
sampl
healthi
particip
collect
beij
sampl
anhui
provinc
sampl
sampl
frozen
bank
variou
institut
collect
sampl
ship
dri
ice
depart
nation
institut
food
drug
control
sampl
thaw
aliquot
store
sampl
studi
subject
ident
treatment
storag
condit
consid
equival
qualiti
pcr
use
construct
recombin
shuttl
plasmid
pscfluc
briefli
firefli
luciferas
gene
photinu
pyrali
plucf
kindli
provid
john
schiller
nation
cancer
institut
bethesda
md
usa
insert
salismai
site
transfer
vector
kindli
provid
b
moss
niaid
nih
usa
control
vacvspecif
earlyl
promot
adjac
gene
encod
lacz
express
screen
marker
recombin
regul
vacv
late
promot
primer
design
inclus
restrict
enzym
site
sali
smai
two
primer
use
test
sens
sali
site
underlin
antisens
smai
site
underlin
amplif
cycl
min
follow
cycl
min
plu
last
extens
min
amplifi
pcr
product
purifi
use
qiaquick
pcr
purif
kit
qiagen
valencia
ca
usa
subject
direct
dna
sequenc
use
autom
abi
dna
sequenc
appli
biosystem
foster
citi
ca
usa
rtvfluc
viru
gener
cef
cell
use
homolog
recombin
method
cef
cell
infect
vtt
multipl
infect
moi
subsequ
transfect
shuttl
vector
pscfluc
design
recombin
specif
tk
gene
vtt
obtain
rtvfluc
recombin
virus
select
bluewhit
plaqu
screen
rtvfluc
viru
propag
purifi
titrat
primari
cef
previous
describ
firefli
luciferasebas
vaccinia
neutral
assay
fluc
assay
neutral
measur
reduct
fluc
report
gene
express
rtvfluc
inhibit
vaccinia
nab
present
serum
sampl
develop
stage
assay
follow
paramet
test
cell
line
incub
time
cell
densiti
wash
pb
viru
concentr
differ
cell
line
vero
primari
cef
screen
determin
infect
profil
rtvfluc
viru
cell
ad
trypsin
singlecel
suspens
viral
progeni
allow
grow
cell
h
infect
cell
densiti
test
cellswel
flatbottom
cultur
plate
corningcostar
tokyo
japan
influenc
wash
pb
luciferas
quantit
test
serial
titer
rtvfluc
viru
determin
optim
viral
dose
assay
consid
natur
infect
viru
vero
cell
variabl
infect
presenc
vari
dilut
serum
contain
vaccinia
nab
involv
pfu
ml
dilut
viru
nine
dilut
antivtt
rabbit
serum
dilut
serum
ml
distribut
three
correspond
well
plate
ml
rtvfluc
viru
ad
well
plate
incub
co
h
follow
incub
ml
cell
ad
well
plate
place
plate
shaker
min
incub
co
h
incub
ml
supernat
aspir
ml
dluciferin
substrat
calip
hopkinton
usa
ad
well
protect
light
room
temperatur
min
luminesc
measur
use
glomax
micropl
luminomet
promega
madison
wi
usa
antivtt
rabbit
serum
atr
use
refer
establish
inhous
standard
serum
sampl
wherea
pool
serum
sampl
individu
preimmun
anim
serum
sampl
fb
use
neg
control
neutral
titer
nt
serum
sampl
defin
serum
dilut
rel
light
unit
rlu
reduc
compar
viruscontain
control
well
subtract
background
rlu
cellcontain
control
well
titer
consid
posit
tradit
control
neutral
assay
perform
accord
optim
protocol
similar
previous
describ
sera
serial
dilut
five
fivefold
dilut
rang
depend
expect
titer
tube
contain
ml
dilut
equal
volum
rtvfluc
viru
pfuml
mix
incub
co
h
ml
ad
vero
cell
duplic
plate
incub
h
co
intermitt
rock
follow
addit
ml
overlay
medium
contain
agaros
day
viral
plaqu
visual
stain
crystal
violet
pb
contain
formaldehyd
count
nt
defin
reciproc
serum
dilut
requir
reduct
rtvfluc
plaqu
neutral
titer
sera
test
prnt
luciferas
compar
varianc
averag
titer
obtain
method
correl
coeffici
calcul
use
student
ttest
comparison
vtt
seropreval
differ
group
evalu
use
chisquar
test
statist
analys
comput
graphpad
prism
graphpad
softwar
san
diego
ca
analys
consid
signific
